CP-0127 (Deltibant) B2R antagonist Phase II Severe traumatic brain injury sepsis Ineffective for sepsis. Discontinued due to unexpected preclinical findings. [48]
LF16-0687 (Anatibant) B2R antagonist Phase II Severe traumatic brain injury Inconclusive results and possible safety issues. Trial halted. [43]
RMP-7 (Lobradimil) B2R agonist Phase II Childhood brain tumors Completed. No improved efficacy [49]
Phase I HIV infection and cryptococcal meningitis Completed, results not available NCT00002316
FOV-2304 (Safotibant) B1R antagonist Phase II Diabetic macular edema Discontinued, results not available. [50,51]
MK-0686 B1R antagonist Phase II Postherpetic neuralgia, postoperative dental pain, osteoarthritis Terminated for postherpetic neuralgia, completed for dental pain and osteoarthritis. No results disclosed [50]
BI-113823 B1R antagonist Phase I Osteoarthritis Terminated NCT01207973
SSR-240612 B1R antagonist Phase II Inflammation and neuropathic pain Halted for undisclosed reasons. [52]
B9870 (Breceptin) Phase I Dual B1R and B2R antagonist
Phase I
Small cell lung cancer
No information available.
[50]